How to design an opioid drug that causes reduced tolerance and dependence. - Wikidata - awgldk - TriplyDB

How to design an opioid drug that causes reduced tolerance and dependence.

How to design an opioid drug that causes reduced tolerance and dependence.

http://www.wikidata.org/entity/Q34144947

about

Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.Opioid receptor trafficking and interaction in nociceptors Endocytosis as a biological response in receptor pharmacology: evaluation by fluorescence microscopy Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC Virtual reality as an adjunctive non-pharmacologic analgesic for acute burn pain during medical procedures.Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418 Chronic ethanol consumption in rats produces opioid antinociceptive tolerance through inhibition of mu opioid receptor endocytosis.Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.A novel knock-in mouse reveals mechanistically distinct forms of morphine tolerance.Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.Experimental psychiatric illness and drug abuse models: from human to animal, an overview Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.Ligand-directed signalling within the opioid receptor family.Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization Association of OPRD1 polymorphisms with heroin dependence in a large case-control series.The Effect of Massage on Anticipatory Anxiety and Procedural Pain in Patients with Burn Injury.Interventional stroke therapies in the elderly: are we helping?Interaction and regulatory functions of μ- and δ-opioid receptors in nociceptive afferent neurons.Use of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues.Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.Safety of intra-arterial treatment in acute ischaemic stroke patients on oral anticoagulants. A cohort study and systematic review.Virtual reality pain control during burn wound debridement of combat-related burn injuries using robot-like arm mounted VR goggles.Breakthrough pain: the importance of baseline analgesic regimen with opioids Low Molecular Weight Opioid Peptide Esters Could be Developed as a New Class of Analgesics A new approach for aggregation of Paramecium caudatum by nitric oxide.Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation.Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants.Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients.Intravenous morphine self-administration alters accumbal microRNA profiles in the mouse brain.Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin.Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.

P2860

Q26796474-FFCB7587-1D81-4948-9969-ED3AE1420143 Q26822251-1B8BC23B-C34C-45A5-BDF5-7446AE793F59 Q27310207-06ED674C-F479-41AD-B607-167F5BF5B102 Q27316789-88B92B33-CC08-40BD-A137-E041B1E21A33 Q30654286-6D433FB0-2016-4EBC-8B1D-026C7868A19E Q33566172-CEEC1FFE-1720-4F1E-B093-AF1E3446B768 Q33908225-EB41B84D-832E-42BC-8A47-70BDAE3254DC Q34006140-5B6CB37C-445C-44EE-BAAD-B4E498C739C3 Q34418517-CAFCC2F6-B761-45D6-A769-846DA98A5843 Q35122864-A00A175D-E6FE-4DF0-8014-1A603D56AAD6 Q35589969-D03D2FB0-223D-4745-B7DD-AD4B0100D317 Q35688547-2164FD37-68EB-4DD5-B03D-EC43BD077FF9 Q35774481-4F849D82-5165-4380-B138-35192EF500DA Q36025329-404D2744-4929-4203-91FF-102D690E73DD Q36382935-2C74D889-B874-4DF5-B749-25C2663368B2 Q36591603-2A591CE1-56AF-4642-A218-46B803B46EEB Q36935273-441C013C-E0E0-410E-A04B-0C7444E8C325 Q37402259-2D4EC23F-B184-49DD-BECC-710038936FD8 Q37683691-0EAEF502-0C0F-48AF-B75C-8AB278325367 Q37960763-14B07543-E1CC-4EE9-B385-CAB657E604E5 Q37998861-4E322EC2-9FF8-4ACB-98BB-98034FCF2D6A Q38078028-10C3F110-AFCE-426B-BDD9-BB08FAFCE7B2 Q38106596-B55859DF-3400-4B53-BAEC-DBEDDBA68161 Q38511030-4C15E19F-05D7-4A1F-86C0-E45978407FFB Q38549778-964080C9-35BC-4566-A234-FEC36765E4BE Q41880809-10A04922-C29B-46ED-B9BB-47C6371C96B6 Q42860558-F743F8CB-E71E-46E0-9C7A-1E14898E1365 Q43243610-E1FAB6C7-AC4D-4E6A-AD60-87E7C33EB7DB Q43505769-8295F9A2-E1FE-4176-A406-D0896862E300 Q44442729-2200CD29-3167-4F34-BEF7-D9F8FD70FDE4 Q47783334-20A92AA8-8543-4A66-BB36-B036CC0769E2 Q48767268-0E49D560-927C-4FA7-9CD9-78FB00C553F2 Q49939866-D482CB5B-659A-4560-A843-A69B11FD0BF8 Q50929144-A29D677B-A85B-47CB-B27C-CE99662E9018 Q53188137-8DA17889-70E4-44BC-98D4-25FAA3691E7C

P2860

How to design an opioid drug that causes reduced tolerance and dependence.

http://www.wikidata.org/entity/Q34144947

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

How to design an opioid drug that causes reduced tolerance and dependence.

@ast

How to design an opioid drug that causes reduced tolerance and dependence.

@en

How to design an opioid drug that causes reduced tolerance and dependence.

@nl

type

label

How to design an opioid drug that causes reduced tolerance and dependence.

@ast

How to design an opioid drug that causes reduced tolerance and dependence.

@en

How to design an opioid drug that causes reduced tolerance and dependence.

@nl

prefLabel

How to design an opioid drug that causes reduced tolerance and dependence.

@ast

How to design an opioid drug that causes reduced tolerance and dependence.

@en

How to design an opioid drug that causes reduced tolerance and dependence.

@nl

P1433

Q34144947-812EBE7F-F728-4F3A-8B59-113DE745C677

P1476

Q34144947-F3246D87-5742-4A4A-889C-1862260BF13D

P2093

Q34144947-32A44B76-3BDE-4705-9379-00B5443DB180

Q34144947-3B275BC6-183D-4A3F-A965-A1562A5C648F

P2860

Q34144947-00BBBE81-0008-49E4-B9A5-A8DD43EDF3C1

Q34144947-03A062BC-0C0C-4863-8209-C4CE4FBE54C8

Q34144947-0659E84B-DEB4-4187-A4B5-D40336B07FC2

Q34144947-0759D1D9-4CD0-4B5B-AA1A-C8C6EA89EAE1

Q34144947-0F01C661-8DF2-4274-BBED-91D15983D5C8

Q34144947-17233D75-72DB-4868-A6AA-544CC499CE42

Q34144947-1A7E89E7-4109-4DA4-A9D9-CD239232E63C

Q34144947-1B91523F-6055-4656-8153-723897A7535E

Q34144947-1DCBE668-CA12-4433-9868-AD3580A01A9B

Q34144947-1F914217-30B7-47B4-9ABF-6F5D56143E4D

P304

Q34144947-E408EC33-E2DE-4127-94B9-BAFDE6A0A671

P31

Q34144947-F7256F5B-E971-41DF-AC23-C664F3A2AF7B

P356

Q34144947-EDC64DA6-DD7B-4E9B-B897-119F59A3FF0C

P433

Q34144947-97EB7106-D042-4734-9321-9427991E1508

P478

Q34144947-CD059C9C-CB88-48A7-A584-1ABDB0B71DDD

P577

Q34144947-969F81C5-36A0-4C40-BAFF-C25E76EDF596

P698

Q34144947-88313046-3755-4d25-a08d-1ef88e2e7455

Q34144947-999E9FC3-D41F-4D12-A048-36B771239449

P921

Q34144947-5c0d8523-34ea-411f-b442-6ebbfa20e4bb

P932

Q34144947-90C7F2F6-F8D6-44BB-8D94-F45EF81F9CCE

P356

ARCHNEUROL.2010.25

P1433

Annals of Neurology

P1476

How to design an opioid drug that causes reduced tolerance and dependence.

@en

P2093

Amy Chang Berger

http://www.w3.org/2001/XMLSchema#string

Jennifer L Whistler

http://www.w3.org/2001/XMLSchema#string

P2860

A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

A brief history of opiates, opioid peptides, and opioid receptors

G-protein-coupled receptor heterodimerization modulates receptor function

Heterodimerization of mu and delta opioid receptors: A role in opiate synergy

Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation

Enhanced morphine analgesia in mice lacking beta-arrestin 2

Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence

Biomarkers of morphine tolerance and dependence are prevented by morphine-induced endocytosis of a mutant mu-opioid receptor.

Opioid rotation for cancer pain: rationale and clinical aspects.

Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment

P304

559-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2010.25

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20437553

http://www.w3.org/2001/XMLSchema#string

P921

P932

2943346

http://www.w3.org/2001/XMLSchema#string